Introduction {#s1}
============

In recent years, natural compound has received more and more attention for use in treating human diseases and conditions, due to their long history of use and various pharmacological therapeutic effects ([@B72]; [@B95]; [@B60]; [@B94]; [@B41]), especially their relative safety (fewer and less severe side effects) than chemical drugs. Naturally occurring triterpenoid can be used as anti-cancer, anti-inflammatory, anti-malarial, and insecticidal agent ([@B12]; [@B35]; [@B31]; [@B11]). It has been proven that some natural or synthetic triterpenoids have promising clinical potential, exhibiting both therapeutic and chemopreventive activities for cancer ([@B64]; [@B1]; [@B30]). Pristimerin (20α-3-hydroxy-2-oxo-24-nor-friedela-1-10,3,5,7-tetraen-carboxylic acid-29-methylester, molecular formula: C~30~H~40~O~4~) ([**Figure 1**](#f1){ref-type="fig"}), a methyl ester of celastrol, is a quinonemethide triterpenoid which has been extracted from a variety of species of the *Celastraceae* and *Hippocrateaceae* families, such as *Hippocratea excels* ([@B50]),*Maytenus heterophylla* ([@B55]), and *Celastrus aculeatus* Merr. ([@B70]). Pristimerin was first isolated in 1951 from *Pristimerae indica* and *P. grahami* and was first identified in 1954 to confirm its molecular structure ([@B34]). Pristimerin has displayed different pharmacological effects, such as anti-cancer, anti-oxidant, anti-inflammatory, anti-bacterial, anti-malarial, and insecticidal activities ([@B22]; [@B4]; [@B26]; [@B46]; [@B31]; [@B81]). As such, it is being developed as a potential anti-cancer drug ([@B93]). Here, we present and discuss current research findings with regard to pristimerin emphasis on the anti-cancer effect.

![Chemical structure of pristimerin.](fphar-10-00746-g001){#f1}

Pristimerin: Broad-Spectrum Anti-Cancer Effect {#s2}
==============================================

Cancer is a complicated disease, which starts with a normal change through the activation of proto-oncogenes or the suppression of tumor suppressor genes ([@B19]). These alterations result in diversed and interactive changes at the level of cellular processes which are involved in the regulation of proliferation, differentiation, apoptosis, migration, and tissue homeostasis. Finally, biological properties for cancer cells are acquired, including infinite proliferation potential, independent exogenous growth factors, and resistance to death signals ([@B5]; [@B15]; [@B61]; [@B66]).

Pristimerin exerts its effects influencing a series of biological properties of cancer cells. Recent studies on a wide range of cancer cell lines of different origins, such as oral cancer ([@B81]), colorectal cancer ([@B92]), glioma ([@B88]), leukemia ([@B47]), breast cancer ([@B86]), lung cancer ([@B96]), and prostate cancer ([@B42]), and also in cancer stem cells ([@B7]). These results have proved that pristimerin possesses strong anti-proliferative activities with involvement of mitochondrial apoptosis, autophagy, and inhibition of nuclear factor kappa B (NF-κB), Akt (protein kinase B, PKB) and mitogen-activated protein kinase (MAPK) ([@B24]; [@B42]; [@B88]; [@B23]; [@B13]).

In view of the potent anti-cancer effect in a broad spectrum (cancer cell lines and molecular targets), it possesses a great potential for pristimerin to develop as a multiple-target anti-cancer drug.

Pristimerin: Anti-Cancer Activities {#s3}
===================================

Growth Inhibition {#s3_1}
-----------------

Pristimerin induces a potent effect of growth inhibition within wide range types of human tumors; the cytotoxicity of pristimerin in different cancer cell lines is summarized in [**Table 1**](#T1){ref-type="table"}.

###### 

The cytotoxicity dosage of pristimerin in different cancer cell lines

  Cancer type                               Time                                                                                    Toxic dosage (IC~50~ value or inhibition rate)                                       References
  ----------------------------------------- --------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ------------
  Prostate cancer                           72 h                                                                                    1.25 µM caused 55% LNCaP cell death                                                  ([@B42])
  1.25 µM caused 47% PC-3 cell death                                                                                                                                                                                     
  Breast cancer                             24 h                                                                                    2.40 µM IC~50~ against SKBR3                                                         ([@B36])
  Colorectal cancer                         72 h                                                                                    1.11 µM IC~50~ against HCT-116                                                       ([@B92])
  48 h                                      1.22 µM IC~50~ against HCT-116                                                          ([@B90])                                                                             
  1.04 µM IC~50~ against SW-620                                                                                                                                                                                          
  0.84 µM IC~50~ against COLO-205                                                                                                                                                                                        
  Hepatocellular carcinoma                  72 h                                                                                    1.44 µM IC~50~ against HepG2                                                         ([@B24])
  1.70 µM IC~50~ µM against HepG2           ([@B80])                                                                                                                                                                     
  0.68 µM IC~50~ µM against Huh7                                                                                                                                                                                         
  0.85 µM IC~50~ µM against Hep3B                                                                                                                                                                                        
  Pancreatic cancer                         24 h                                                                                    0.66 µM, 0.97 µM, 0.13 µM, IC~50~ against BxPC-3, PANC-1, and AsPC-1, respectively   ([@B79])
  48 h                                      0.28 µM, 0.34 µM, and 0.38 µM IC~50~ against BxPC-3, PANC-1, and AsPC-1, respectively                                                                                        
  72 h                                      0.19 µM, 0.26 µM and 0.30 µM IC~50~ against BxPC-3, PANC-1, and AsPC-1, respectively                                                                                         
  Glioma                                    6 h                                                                                     4.5 µM IC~50~ against U251                                                           ([@B97])
  5.0 µM IC~50~ against U87                                                                                                                                                                                              
  Leukemia                                  72 h                                                                                    0.61 µM IC~50~ against HL-60                                                         ([@B10])
  1.49 µM IC~50~ against K562                                                                                                                                                                                            
  72 h                                      199 nM IC~50~ against KBM5                                                              ([@B47])                                                                             
  135 nM IC~50~ against KBM5-T315I                                                                                                                                                                                       
  450 nM IC~50~ against K562                                                                                                                                                                                             
  Ovarian carcinoma                         72 h                                                                                    1.25 µM caused 44% OVCAR-5 cell death                                                ([@B23])
  1.25 µM caused 28% MDAH-2774 cell death                                                                                                                                                                                
  2.5 µM caused 36% SK-OV-3 cell death                                                                                                                                                                                   
  2.5 µM caused 27% OVCAR-3 cell death                                                                                                                                                                                   
  Osteosarcoma                              24 h                                                                                    0.80 µM IC~50~ against MNNG                                                          ([@B52])
  0.54 µM IC~50~ against 143B                                                                                                                                                                                            
  48 h                                      0.39 µM IC~50~ against MNNG                                                                                                                                                  
  0.31 µM IC~50~ against 143B                                                                                                                                                                                            
  72 h                                      0.32 µM IC~50~ against MNNG                                                                                                                                                  
  0.29 µM IC~50~ against 143B                                                                                                                                                                                            
  Oral cancer                               72 h                                                                                    0.54 µM IC~50~ against KB                                                            ([@B87])
  0.52 µM IC~50~ against KBv200                                                                                                                                                                                          
  0.70 µM IC~50~ against CAL-27             ([@B81])                                                                                                                                                                     
  0.73 µM IC~50~ against SCC-25                                                                                                                                                                                          
  ESCC                                      72 h                                                                                    1.98 µM IC~50~ against EC9706                                                        ([@B74])
  1.76 µM IC~50~ against EC109                                                                                                                                                                                           
  1.13 µM IC~50~ against KYSE30                                                                                                                                                                                          

ESCC, esophageal squamous cell carcinoma.

Apoptosis Induction {#s3_2}
-------------------

Apoptosis is a kind of programmed cell death, whose activation is regulated by a series of genes, in the purpose of eliminating redundant, damaged, even infected cells to maintain homeostasis ([@B30]). Anti-cancer agents killing tumor cells by the induction of apoptosis is generally studied ([@B83]; [@B85]; [@B62]). Two main subtypes of apoptosis have been divided into the intrinsic mitochondrial pathway and the extrinsic death receptor pathway ([@B19]).

In the mitochondrial pathway, Bcl-2 family members converge on mitochondria ([@B29]), regulating release of various mitochondrial components to form the apoptosome ([@B17]), such as cytochrome *c* associated with Apaf-1 and procaspase-9 ([@B20]). In the death receptor pathway, stimulation of death receptors, including Fas and tumor necrosis factor (TNF) receptor-1, results in the assembly of death-inducing signaling complex, containing the adapter protein ([@B25]), Fas-associated death domain, and initiator caspases, such as caspase-8 ([@B58]).

Pristimerin-induced apoptotic effects were mainly due to mitochondrial dysfunction, activation of both extrinsic and intrinsic caspases, and cleavage of poly ADP-ribose polymerase (PARP). It has been reported that pristimerin can induce caspase-dependent apoptosis in human glioma cancer cells ([@B88]), pancreatic cancer cells ([@B14]), and hepatoma cancer cells ([@B23]). Pristimerin-induced inhibition of Bcl-2 (as well as Bcl-2 mRNA) is sufficient to promote mitochondrial permeability transition and release of cytochrome *c* mediated by Bax and Bak without the inhibition of Bcl-xL in pancreatic cancer cells ([@B14]). On the other hand, caspase inhibitor failed to antagonize the effects of pristimerin, indicating that the lethal effect of pristimerin may not be caspase-dependent in human glioma U251 and U87 cells ([@B97]).

The apoptotic effect of pristimerin is related to Bcl-2, and it mediates down-regulation of Bcl-2 through reactive oxygen species (ROS)-dependent ubiquitin-proteasomal degradation pathway in human prostate cancer LNCaP and PC-3 cells ([@B42]). ROS-induced apoptosis by pritimerin was also reported in hepatocellular carcinoma HepG2 cells, involving EGFR and Akt proteins ([@B24]). In colorectal carcinoma cells, the associated induction of JNK activation and MMP loss was observed ([@B91]), similar with the results in cervical cancer cells ([@B6]).

In human colon cancer cells, pristimerin caused cell cycle arrest and apoptosis through cyclin-CDK, mitochondrial dysfunction, and caspase-dependent mechanisms. Besides, the inhibition of DNA synthesis in HL-60 was also associated with pristimerin-induced apoptosis ([@B10]).

Pristimerin-induced apoptosis could be mediated by microRNA (miRNA). miRNAs exert a post-transcriptional gene silencing effect through binding to target mRNA and endonucleolytic cleavage of the mRNA by protein argonaute-2 (AGO2) ([@B32]). It was reported that pristimerin induced apoptosis through inhibiting AGO2 and PTPN1 expression *via* miR-542-5p in glioma cancer cells U373 ([@B40]). Synergization with cisplatin, pristimerin led to apoptosis *via* inhibiting the miR-23a, regulating PTEN/Akt signaling-related PTEN and the phosphorylation of Akt and GSK3β in lung carcinoma NCI-H446 and A549 cells ([@B96]).

Autophagy Induction {#s3_3}
-------------------

As another programmed necrosis, autophagy is a homeostatic cellular self-digestive process. Autophagy triggered by various cellular stress plays vital role in cell death, providing novel target for developing anti-cancer drug ([@B51]; [@B63]). LC3-II promotes the expansion and maturation of autophagy, which is considered as signal of autophagy activation. Pristimerin-induced autophagy was reported in human breast cancer MDA-MB-231 ([@B7]; [@B38]) and MCF-7 cells ([@B7]). As evidenced by the increase of p62 and LC3-II with an unfolded protein response (UPR), pristimerin induced an incompleted autophagy through Wnt signaling. Although endoplasmic reticulum (ER) stress is also a trigger of autophagy ([@B67]), it was not concluded whether the observed ER stress by pristimerin induced autophagy ([@B7]). Additionally, a combination treatment of pristimerin and paclitaxel strengthened the extracellular signal-related kinase (ERK)-dependent autophagic cell death, with increase of p62 degradation and beclin1 expression ([@B38]).

On the contrary, pristimerin suppressed autophagy, downregulating LC3BII and beclin1 to sensitize the apoptosis caused by cisplatin in lung carcinoma A549 and NCI-H446 cells ([@B96]).

Inhibition of Metastasis, Migration, Invasion, Angiogensis, and Cancer Stem Cell {#s3_4}
--------------------------------------------------------------------------------

The cancer metastases include a series of process, such as the completion of a complex succession of cell-biological event, cancer cell invasion, migration, and forming metastatic colonization in clinic ([@B75]). Pristimerin was reported to inhibit migration and invasion *via* targeting G protein signaling 4 (RGS4) in breast cancer MDA-MB-231 cells ([@B53]) and HER2 in human breast carcinoma SKBR3 cells ([@B36]). Furthermore, mammalian target of rapamycin (mTOR) may be associated with its upstream Akt in pristimerin-induced inhibition of migration and invasion in colorectal cancer HCT-116 cells ([@B91]). Pristimerin suppressed the invasion of human prostate cancer PC-3 cells through inhibition of epithelial-to-mesenchymal transition (EMT), which was confirmed by the EMT-related markers ([@B8]), including N-cadherin, fibronectin, vimentin and ZEB1 ([@B98]). MMP2 and MMP9, which are important proteins regulating invasion and metastasis, were decreased by pristimerin in esophageal cancer EC9706 and EC109 cells in a dose-dependent manner, resulting in inhibition of migration and invasion ([@B74]).

To supply nutrients and clear metabolic wastes, novel capillary blood vessels grow from pre-existing vasculature, which is called angiogenesis. However, aberrant angiogenesis plays a key role in cancer development ([@B75]). Thus, anti-angiogenic therapy is promising and under development ([@B39]). Pristimerin was reported to *in vivo* inhibit the neovascularization of chicken chorioallantoic membrane (CAM) and vessel *ex vivo* sprout in rat aortic ring assay, through a vascular endothelial growth factor (VEGF)-dependent mechanism ([@B54]). Also, the decreased-VEGF by pristimerin was reported through the inhibition of HIF-1α *via* the SPHK-1 signaling pathway in hypoxic prostate cancer PC-3 cells ([@B37]). In addition, pristimerin-induced cancer stem cell toxicity was observed in breast cancer stem cells ([@B7]) and esophageal squamous cell carcinoma (ESCC) ([@B74]).

Reversal of Drug Resistance {#s3_5}
---------------------------

Multi-drug resistance (MDR) is defined as the resistance of cancer cells not limited to a specific chemotherapeutic drug through different structures and mechanisms of action ([@B82]). ABCB1 (P-glycoprotein, Pgp) is recognized as putative drug transporter, which is encoded by the ABCB1 gene, one of (ATP)-binding cassette (ABC) transporter family ([@B16]). Pristimerin may overcome ABCB1-mediated chemotherapeutic drug resistance through disturbing the stability of ABCB1 independent of its mRNA expression in human oral epidermoid carcinoma cells KBv200 ([@B87]). In addition, with inhibition of NF-κB and Bcr-Abl, pristimerin is effective *in vitro* and *in vivo* against imatinib-resistant chronic myelogenous leukemia cells ([@B47]). Additionally, Akt signaling was related to the reversal of MDR in multidrug-resistant MCF-7/ADR breast cancer cells ([@B86]).

Synergization With Chemotherapeutic Drugs {#s3_6}
-----------------------------------------

Drug combination for cancer treatment has been well established to strengthen the anti-tumor action in varied aspects ([@B27]; [@B2]), including therapeutic drug combination with natural product ([@B18]; [@B65]). Pristimerin was reported to synergize with paclitaxel in human breast cancer cells ([@B38]), with 5-fluorouracil (5-FU) in esophageal ESCC ([@B74]). In cervical cancer cells, combination with taxol could induce cell death through ROS-mediated mitochondrial dysfunction ([@B21]). In NCI-H446 and A549 lung carcinoma cells, combination with cisplatin could induce cell apoptosis through inhibiting the miRNA-23a and Akt/GSK3β signaling pathway ([@B96]). In pancreatic cancer cells, pristimerin could potentiate the cytotoxic effect of gemcitabine with the possible mechanism being the inhibition of gemcitabine-induced NF-κB activation ([@B79]).

*In Vivo* Anti-Tumor Activities {#s3_7}
-------------------------------

Pristimerin was widely reported its *in vivo* anti-tumor activities, which is summarized in [**Table 2**](#T2){ref-type="table"}.

###### 

*In vivo* anti-tumor activities of pristimerin.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Models                                                          Dose and administration                                               Activities                                                                                                                      Mechanisms                                                                                              References
  --------------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------
  Human breast tumor xenograft model                              3 mg/kg/2 days, s.c.                                                  Reduced both tumor volume and tumor weight, inhibited tumor angiogenesis.                                                       Associated with decreased secretion of proangiogenic molecules (VEGF)                                   ([@B54])

  Human breast tumor xenograft model                              1 mg/kg/2 days, s.c.                                                  Inhibited the growth of implanted tumors, inhibited the invasiveness                                                            ---                                                                                                     ([@B53])

  Orthotopic HCC patient-derived xenograft model                  1 mg/kg/3 times/week, i.v.                                            Caused significant reductions in tumor volumes of xenografts                                                                    Disrupt HSP90 and CDC37 interaction, inhibit Raf/MEK/ERK and PI3K/AKT/mTOR pathways                     ([@B80])

  Intra-tibial injection model                                    7.5 × 10^3^ cells/µl 1.6 µM pristimerin pre-treated 24 h PC-3 cells   Inhibited the bone destruction by the invasion of the tumor, reduced the tumorigenic potential of bone metastasis               ---                                                                                                     ([@B28])

  Human glioma xenograft model                                    1 and 3 mg/kg/2 days, s.c.                                            Inhibited glioma volume and weight *in vivo* in a dose-dependent manner                                                         Up-regulated JNK level the phosphorylated JNK, upregulated the nuclear AIF and the ratio of Bax/Bcl-2   ([@B97])

  AOM/DSS model of colitis-associated colorectal carcinogenesis   fed with 1 to 5 ppm pristimerin                                       Reduced tumor burden                                                                                                            ---                                                                                                     ([@B57])

  Human ESCC xenograft model                                      1 mg/kg/2 days, i.t.                                                  Inhibited the growth and weight of tumor, suppressed proliferation                                                              ---                                                                                                     ([@B74])

  Human colorectal cancer xenograft model                         1 mg/kg/2 days, i.p.                                                  Inhibited tumor growth                                                                                                          Mainly through suppressing NF-кB activity and p65 phosphorylation                                       ([@B92])

  Human lung tumors xenograft model                               0.8 mg/kg pristimerin and 2 mg/kg cisplatin, s.c.                     Enhanced the effect of cisplatin to decrease tumor volumes and weights                                                          Inhibited the phosphorylation of Akt and GSK3β                                                          ([@B96])

  Human osteosarcoma xenograft model                              1 mg/kg/2 days, i.p.                                                  Reduced both tumor volume and tumor weight                                                                                      ---                                                                                                     ([@B52])

  Human colorectal cancer xenograft model                         1 mg/kg/2 days, i.p.                                                  Inhibited the growth of\                                                                                                        Induced apoptosis through an increment in cleaved caspase-3                                             ([@B91])
                                                                                                                                        implanted tumors                                                                                                                                                                                                                        

  Human myeloma xenograft model                                   2.5 mg/kg per day, s.c.                                               Inhibited growth of human myeloma xenograft, diminished toxicity in a liposomal dose                                            ---                                                                                                     ([@B73])

  Human breast cancer xenograft model                             1 mg/kg for 2 days, i.p.                                              Decreased tumor size and weights, slightly reduced toxicity and behavioral changes in an E/T80/WFI carrier compared to D/PBS.   ---                                                                                                     ([@B7])
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*s.c. represents subcutaneously, i.v. for intravenously, i.t. for intratumorly, i.p. for intraperitoneally, and ppm for parts per million, respectively. ERK, extracellular signal-related kinase.

Pristimerin in Tumors: Targets and Pathways {#s4}
===========================================

Proteasome {#s4_1}
----------

As another important mechanism of maintaining homeostasis, proteasome-mediated degradation is associated with essential cellular processes, regulating the vast majority of cellular proteins ([@B45]). Consistent with triterpenoids being reported to target proteasome ([@B9]; [@B73]), pristimerin also showed a potent activity to inhibit proteasome activity in prostate cancer cells ([@B89]; [@B42]; [@B43]), breast cancer cells ([@B53]), cervical carcinoma cells ([@B21]), and myeloma cells ([@B73]).

The β subunits of proteasome contain active protease sites with different peptidase activities, including caspase-like or peptidyl-glutamyl peptide-hydrolyzing-like (β1), trypsin-like post basic (β2), and chymotrypsin-like (β5) activities ([@B49]). Pristimerin was associated with the N-terminal threonine of the β5 subunit through its conjugated ketone carbon C~6~, exerting a chymotrypsin-like activity ([@B89]), which is also associated with RGS4 ([@B53]).

Pristimerin can inhibit Bcl-2, finally induced mitochondrial cell death *via* an ROS-dependent ubiquitin-proteasomal degradation pathway ([@B42]). Pristimerin combination with taxol caused mitochondrial apoptosis due to ROS generation and direct proteasome inhibition ([@B21]). In addition, pristimerin-induced inhibition of proteosome and IKK phosphorylation of IκB together led to UPR and suppression of NF-κB activity and cyclin D2 expression in myeloma cells H929 and U266 ([@B73]).

Telomerase {#s4_2}
----------

Telomere is a ribonucleoprotein complex located in the end of chromosomes, maintaining telomere length homeostasis to keep chromosomal stability ([@B78]). Due to the differences in telomere homeostasis between cancer and normal cells, targeting telomerase may be a promising approach to find effective and safe anti-cancer treatments ([@B3]).

Pristimerin can inhibit telomerase activity in human prostate cancer LNCaP and PC-3 cells ([@B44]). The mechanism is related to inhibition of human telomerase reverse transcriptase (hTERT) and its mRNA expression, which codes the catalytic subunit of the telomerase. At the same time, knocking-down of hTERT strengthened the effects of pristimerin. Furthermore, hTERT regulatory proteins c-Myc, Sp1, p-STAT3, and p-Akt were inhibited in a dose-dependent manner ([@B44]).

MAPK Pathway {#s4_3}
------------

The generic MAPK signaling pathway is co-regulated by four different cascades including extracellular signal-related kinases (ERK1/2), Jun amino-terminal kinases (JNK1/2/3), p38-MAPK, and ERK5 ([@B69]). MAPK/ERK pathway regulates the cell proliferation ([@B68]), differentiation ([@B76]), migration ([@B71]) and apoptosis ([@B77]).

Pristimerin-induced autophagy was reported *via* ERK1/2 in human breast cancer cells when combination with paclitaxel ([@B38]). ERK1/2 may be involved in pristimerin-induced intrinsic apoptosis in human oral epidermoid carcinoma cells ([@B87]) and in human glioma cells ([@B88]). Both JNK and PARP-1 *via* ROS pathway are essentially required for the pristimerin-induced intrinsic apoptosis in human cervical cancer cells ([@B6]). In addition, ERK1/2 suppression occurred in VEGF-induced capillary-like structure formation of human umbilical vascular endothelial cells (HUVECs) ([@B54]). These activities were accompanied with Akt inhibition ([@B54]; [@B87]; [@B38]).

PI3K/AKT/mTOR Pathway {#s4_4}
---------------------

The phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway cascade containing PI3K, AKT, and mTOR is the most frequently altered pathway in human for cancer development, such as cell cycle, cell survival, metabolism, motility, angiogenesis, chemoresistance, and genomic instability ([@B48]).

Pristimerin showed a potent apoptosis-inducing anti-proliferative activity in human osteosarcoma cells ([@B52]) by PI3K/AKT/mTOR pathway. The pristimerin-induced ROS-dependent mitochondrial cell apoptosis was also associated with the inhibition of EGFR and Akt in human glioma cells ([@B88]). It was confirmed that PI3K/AKT/mTOR pathway-activated activities were accompanied by the downstream Foxo-3α, cyclin D1 and Bcl-XL (Akt), p-S6K1, and p-4E-BP1 (mTOR) as well as p21, p27, and PKCε in human ovarian cancer cells ([@B14]; [@B23]; [@B57]). Furthermore, downstream Bad and Bcl-xL pointed to drug resistance in MCF-7/ADR human breast cancer cells ([@B86]). In addition, pristimerin suppressed angiogenesis through VEGF-induced Akt, ERK1/2, mTOR, and ribosomal protein S6 kinase ([@B54]).

NF-κB Pathway {#s4_5}
-------------

NF-κB family transcription factors are crucial regulators of cell survival and inflammatory processes ([@B56]). The inactive NF-κBs are isolated from nucleus by inhibitor of NF-κB (IκB) proteins. When activated IKK (IκB kinase) makes a proteasomal degradation of IκB, the subsequent process will occur, including the release of NF-κB, translocation of NF-κB nuclear and activation of gene transcription. NF-κB can be activated by both intracellular and extracellular stimuli, including cytokines (TNF-α, IL-1β), bacterial, and viral products (LPS) ([@B84]).

NF-κB-regulated anti-apoptotic Bcl-2, Bcl-xL, c-IAPl, and surviving in human ovarian carcinoma cells ([@B23]), Cox-2 and VEGF in human pancreatic cancer cells ([@B14]). NF-κB pathway may link anti-tumor activity of pristimerin and its anti-inflammatory properties ([@B57]). Pristimerin suppressed the translocation of NF-κB nuclear; however, there was no change of the total NF-κB protein in pancreatic cancer ([@B79]). In contrast, pristimerin inhibited both genetic expression and activation of NF-кB protein with suppression of p65 mRNA in human colorectal cancer cells ([@B92]). TNFα-induced NF-κB activation was observed by the downstream MMP9, cyclin D1, and c-Myc in ESCC cells ([@B74]). When combined with pristimerin, the inactivation of Bcr-Abl by imatinib did not interfere with the TNFα-induced NF-κB activation, which implicated that NF-κB inactivation and Bcr-Abl inhibition may be parallel mechanisms of pristimerin-induced activity in human chronic myelogenous leukemia cells ([@B47]). G1 phase arrest was also associated with NF-κB pathway in human pancreatic cancer cells ([@B79]), as well as proteosome in human myeloma cells ([@B73]). Moreover, pristimerin inhibited expression of miR-542-5p targeting PTPN1, which encodes protein tyrosine phosphatase 1B (PTP1B) related to NF-κB pathway ([@B40]).

Wnt/β-Catenin Pathway {#s4_6}
---------------------

Wnt proteins are key mediators in a series of important cellular process. The abnormal activation of Wnt/β-catenin pathway can cause a wide range of diseases including cancers ([@B33]; [@B59]). Pristimerin was reported to suppress Wnt/β-catenin pathway through targeting and inhibiting the expression of LRP6 and its phosphorylation, which may contribute to autophagy in human breast cancer MCF-7 cells ([@B7]).

Conclusions and Perspective {#s5}
===========================

Plants, particularly medicinal herbs, have become increasingly popular due to their potent therapeutic effects. Pristimerin, a quininemethide triterpenoid compound isolated from species of the *Celastraceae* and *Hippocrateaceae* families, has displayed biological and pharmacological activities, particularly inhibiting cancer. This review summarizes the reported results on anti-cancer activities and related mechanisms of pristimerin.

Pristimerin has shown anti-cancer potency *in vivo* ([**Table 2**](#T2){ref-type="table"}) and *in vitro* ([**Table 3**](#T3){ref-type="table"}) *via* specific mechanisms ([**Figure 2**](#f2){ref-type="fig"}). Like many other chemotherapeutic drugs, pristimerin exerts cytotoxicity largely related to apoptosis, while the mechanism of autophagy is merely reported. The cross-talk of apoptosis and autophagy mediated by pristimerin is still remained to be explored. So far, the mechanism study of pristimerin has little reported on lung cancer, epigenetic regulation, and combination with immunotherapy. Furthermore, pristimerin has been reported to have poor selective toxicity in some cancer cells or compared with its derivatives ([@B10]; [@B80]). Comprehensive evaluation of pristimerin toxicity is yet to be carried out (as well as clinical trials). In summary, pristimerin possesses potent anti-cancer effect and further study will bring about novel drug development based on pristimerin.

###### 

Anti-cancer mechanisms of pristimerin in different cell lines.

  Cancer type                                                                                                                                            Cell lines                                                                                               Mechanisms                                                                                                                                           References
  ------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Prostate cancer                                                                                                                                        PC-3                                                                                                     Inhibited HIF-1α accumulation by inhibiting SPHK-1                                                                                                   
  Inhibited CD133 and CD44 protein expression, reduced VEGF                                                                                              ([@B28])                                                                                                                                                                                                                                                      
  LNCaP and PC-3                                                                                                                                         Down-regulated Bcl-2 through an ROS-dependent ubiquitin-proteasomal degradation pathway                  ([@B42])                                                                                                                                             
  Prevented survivin *via* the ubiquitin-proteasome pathway                                                                                              ([@B43])                                                                                                                                                                                                                                                      
  Inhibited hTERT expression *via* the inhibition of SP1, c-Myc, STAT3, and B/Akt                                                                        ([@B44])                                                                                                                                                                                                                                                      
  Breast cancer                                                                                                                                          SKBR3                                                                                                    Down-regulated HER2, decreased fatty acid synthase                                                                                                   ([@B36])
  MDA-MB-231                                                                                                                                             Suppressed proteasomal activity *via* increasing the levels of RGS4                                      ([@B53])                                                                                                                                             
  Suppressed the LC3-II levels of this on ERK signaling when combination with paclitaxel                                                                 ([@B38])                                                                                                                                                                                                                                                      
  Colorectal cancer                                                                                                                                      HCT-116                                                                                                  Inhibited the AKT/FOXO3a pathway *via* decreasing cyclinD1 and Bcl-XL, increased the expression of p21 and p27                                       ([@B57])
  HCT-116                                                                                                                                                Inhibited activated NF-кB, TNFα, and activated LPS-induced NF-кB signaling pathway                       ([@B92])                                                                                                                                             
  HCT-116, COLO-205, and SW-620                                                                                                                          Inhibited of phosphorylated EGFR and HER2 expression, caused inhibition of related downstream kinases.   ([@B90])                                                                                                                                             
  Hepatocellular carcinoma                                                                                                                               HepG2                                                                                                    Generated ROS, induced release of cytochrome *c*, and down-regulated EGFR protein                                                                    ([@B24])
  Disrupted HSP90/CDC37 interaction, degraded and inhibited phosphorylation of protein kinases in the Raf/MEK/ERK and PI3K/AKT/mTOR signaling pathways   ([@B80])                                                                                                                                                                                                                                                      
  Pancreatic cancer                                                                                                                                      BxPC-3, PANC-1, and AsPC-1                                                                               Inhibited of the translocation and DNA-binding activity of NF-κB                                                                                     ([@B79])
  MiaPaCa-2 and Panc-1                                                                                                                                   Inhibited of hTERT *via* suppressing the transcription factors Sp1, c-Myc, and NF-κB                     ([@B13])                                                                                                                                             
  Glioma                                                                                                                                                 U87                                                                                                      Activated of JNK through overproduction of ROS                                                                                                       ([@B97])
  U373                                                                                                                                                   Targeting AGO2 and PTPN1 expression *via* miR-542-5p                                                     ([@B40])                                                                                                                                             
  Myeloma                                                                                                                                                H929 and U266                                                                                            Both inhibited IKK phosphorylation of IκB and proteosome, causing unfolded protein response and suppressing NF-κB activity and cyclin D expression   ([@B73])
  Cervical cancer                                                                                                                                        HeLa                                                                                                     Activated ROS-dependent JNK, Bax, and PARP-1                                                                                                         ([@B21])
  Leukemia                                                                                                                                               HL-60                                                                                                    Interfered DNA synthesis                                                                                                                             ([@B10])
  KBM5 and KBM5-T3151                                                                                                                                    Depleted Bcr-Abl, activated TAK1TIKK and IKKTIκBα in NF-κB signaling parallel but independent            ([@B47])                                                                                                                                             
  Ovarian carcinoma                                                                                                                                      OVCAR-5, MDAH-2774, OVCAR-3, and SK-OV-3                                                                 Inhibited prosurvival signaling proteins Akt, mTOR and NF-kB; inhibited NF-κB-regulated anti-apoptotic proteins Bcl-2, Bcl-xL, c-IAPl and survivin   ([@B23])
  Osteosarcoma                                                                                                                                           MNNG and 143B                                                                                            Decreased expression of Akt, mTOR, and NF-κB                                                                                                         ([@B52])
  Oral cancer                                                                                                                                            KBv200                                                                                                   Decreased P-gp through interrupt protein stability in MAPK and PI3K/Akt pathways                                                                     ([@B87])
  CAL-27 and SCC-25                                                                                                                                      G1 phase arrest and MAPK/Erk1/2 and Akt signaling inhibition                                             ([@B81])                                                                                                                                             
  ESCC                                                                                                                                                   EC9706, EC109, and KYSE30                                                                                Inhibited NF-κB pathway, synergistic effect with 5-FU                                                                                                ([@B74])

ESCC, esophageal squamous cell carcinoma; ROS, reactive oxygen species.
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